gemcitabin

Phase 3Small molecule

gemcitabin is one of 139 small molecule programs targeting Pancreatic Ductal Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

138

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic Ductal AdenocarcinomaActive, not recruiting

Biliary Tract CancerActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Diffuse Large B-Cell LymphomaActive, not recruiting

Pancreatic Ductal AdenocarcinomaPhase 1

Active, not recruiting

Biliary Tract CancerPreclinical

Active, not recruiting

Non-Small Cell Lung CancerPhase 3

Active, not recruiting

Diffuse Large B-Cell LymphomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

gemcitabin

GGerman Cancer Research Center

Phase 3

1 2

Gemzar

GGynecologic Oncology Group

Preclinical

72 3

Imjudo

AstraZeneca

Preclinical

5 4

Gilotrif

Boehringer Ingelheim

Preclinical

12 5

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 6

Remeron

OOrganon and Co

Preclinical

1 7

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 8

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

2 9

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

REGN2810

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Active, not recruiting

Diffuse Large B-Cell Lymphoma

NCT07480850

Q1 2029

Not yet recruiting

Biliary Tract Cancer

NCT07466238

Clinical

Trials by Indication[1]

Relapsed/Refractory1 trial

GPED Regimen for Relapsed/Refractory or Advanced ENKTCL

Unknown status·—·Phase 2·NCT04405375·29 enrolled

Non-Small Cell Lung Cancer1 trial

Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR

Completed·SSpanish Lung Cancer Group·Phase 3·NCT00446225·174 enrolled

Pancreatic Ductal Adenocarcinoma1 trial

A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients with Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma

Terminated·GGerman Cancer Research Center·Phase 1·NCT05494866·6 enrolled

Diffuse Large B-Cell Lymphoma1 trial

Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma

Active, not recruiting·—·Phase 2·NCT07480850·40 enrolled

Biliary Tract Cancer1 trial

HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer

Not yet recruiting·PPeking University··NCT07466238·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for gemcitabin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — gemcitabin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for gemcitabin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — German Cancer Research Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GGerman Cancer Research Center

gemcitabin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q1 2029

Trials by Indication[1]

Relapsed/Refractory1 trial

Non-Small Cell Lung Cancer1 trial

Pancreatic Ductal Adenocarcinoma1 trial

Diffuse Large B-Cell Lymphoma1 trial

Biliary Tract Cancer1 trial

References

Drug Info

Quick Facts

Related News